Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines

Licensing and decisions on public health use of a vaccine rely on a robust clinical development program that permits a risk-benefit assessment of the product in the target population. Studies undertaken early in clinical development, as well as well-designed pivotal trials, allow for this robust cha...

Full description

Bibliographic Details
Main Authors: Vannice, Kirsten S., Wilder-Smith, Annelies, Barrett, Alan D.T., Carrijo, Kalinka, Cavaleri, Marco, de Silva, Aravinda, Durbin, Anna P., Endy, Tim, Harris, Eva, Innis, Bruce L., Katzelnick, Leah C., Smith, Peter G., Sun, Wellington, Thomas, Stephen J., Hombach, Joachim
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Journal Article
Language:English
Published: 2018
Subjects:
Dengue
Dengue vaccine
Online Access:https://hdl.handle.net/10356/83868
http://hdl.handle.net/10220/45083

Internet

https://hdl.handle.net/10356/83868
http://hdl.handle.net/10220/45083

Similar Items